Utilizing Vascular Integrins as a Therapeutic Target for Acute & Long-COVID

Time: 11:00 am
day: Day One


  • Vascular integrins including alpha5beta1 and alphavbeta3 are experimentally validated receptors for SARS-CoV-2
  • Acute blockade of these integrins with clinically validated inhibitors can reduce SARS-CoV-2 infection
  • Chronic blockade of these integrins may also be therapeutic in cerebrovascular manifestations of long-COVID